08.19.13
A new clinical trial on Next Pharmaceuticals’ Relora found that a proprietary blend of Magnolia officinalis and Phellodendron amurense significantly improved mood and other psychological states in moderately stressed subjects. The study, which was conducted by Supplement Watch/GLH Nutrition, has been accepted for publication in the Journal of the International Society of Sports Nutrition 2013, 10:37.
The trial randomly assigned 60 subjects (56 of whom successfully completed the study) experiencing moderate levels of perceived psychological stress to take Relora or a placebo twice a day for four weeks, a time period selected to minimize the influence of short-term mood changes that result from daily stressors. All subjects submitted three saliva samples (morning, mid-day and evening) for cortisol testing and completed a baseline Profile of Mood States questionnaire (POMS) on the first and last day of the study.
The results indicated that daily use of Relora reduced cortisol exposure and perceived stress while improving a variety of mood parameters — most significantly, anger (reduced by 42%) and fatigue (reduced by 31%).
Other indicators measured in the study include overall stress (reduced by 11%), tension (reduced by 13%), depression (reduced by 20%) and confusion (reduced by 27%). Salivary cortisol exposure decreased by 18%. No adverse side effects were reported.
The Relora Clinical Trial will be the topic of a seminar at this year’s SupplySide West Conference on Thursday, November 14, from 10:00-10:50am in the Sands Conference Room 101-102.
For more information: www.nextpharmaceuticals.com
The trial randomly assigned 60 subjects (56 of whom successfully completed the study) experiencing moderate levels of perceived psychological stress to take Relora or a placebo twice a day for four weeks, a time period selected to minimize the influence of short-term mood changes that result from daily stressors. All subjects submitted three saliva samples (morning, mid-day and evening) for cortisol testing and completed a baseline Profile of Mood States questionnaire (POMS) on the first and last day of the study.
The results indicated that daily use of Relora reduced cortisol exposure and perceived stress while improving a variety of mood parameters — most significantly, anger (reduced by 42%) and fatigue (reduced by 31%).
Other indicators measured in the study include overall stress (reduced by 11%), tension (reduced by 13%), depression (reduced by 20%) and confusion (reduced by 27%). Salivary cortisol exposure decreased by 18%. No adverse side effects were reported.
The Relora Clinical Trial will be the topic of a seminar at this year’s SupplySide West Conference on Thursday, November 14, from 10:00-10:50am in the Sands Conference Room 101-102.
For more information: www.nextpharmaceuticals.com
